Answers are grounded in this paper and cite their sources.
Cardiovascular–Kidney–Metabolic (CKM) syndrome, a term introduced by the American Heart Association (AHA) in 2023, reflects the growing recognition of how metabolic dysfunction drives multi-organ pathology through interconnected pathways. This review examines the pathophysiological mechanisms underlying CKM syndrome and evaluates emerging therapeutic strategies. CKM syndrome is driven by the interplay of insulin resistance, chronic inflammation and oxidative stress, activation of the renin–angiotensin–aldosterone system. These mechanisms converge to promote fibrosis, insulin resistance, and end-organ damage across the cardiovascular and renal systems. Therapeutic advances include Sodium–Glucose Cotransporter 2 inhibitors, which demonstrate consistent cardiorenal benefits across heart failure phenotypes and chronic kidney disease. Glucagon-like peptide-1 receptor agonists, including semaglutide and the dual GIP/GLP-1 agonist, tirzepatide, achieve substantial weight reduction and improve cardiovascular, renal, and hepatic outcomes in selected study populations. Non-steroidal mineralocorticoid receptor antagonists, particularly finerenone, offer cardiorenal protection with an improved safety profile, while aldosterone synthase inhibitors represent a promising frontier. The pathophysiological processes involved in CKM also generate a distinct atherogenic dyslipidaemic phenotype, which means effective lipid management has the potential to reduce residual cardiovascular and renal risk in patients with CKM syndrome. Novel potassium binders may also be part of CKM syndrome treatment strategies to reduce hyperkalaemia risk. Despite these advances, questions remain regarding the optimal combination strategies in CKM syndrome. There are also no studies designed to assess treatment efficacy in groups stratified according to the CKM syndrome framework. Future research should prioritise mechanistic studies and large-scale trials evaluating long-term outcomes across the full CKM spectrum.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: